SiPhox Health vs Vinci
Side-by-side comparison of AI visibility scores, market position, and capabilities
MIT-founded home blood testing company measuring 17 biomarkers via mail-in kits; Khosla-backed developing photonic chip for instant at-home results competing with Everlywell.
About
SiPhox Health is a home blood testing company founded by MIT scientists that provides mail-in blood test kits measuring 17 key biomarkers — inflammation markers (CRP, homocysteine), cardiovascular health (LDL, HDL, triglycerides, ApoB), metabolic health (HbA1c, glucose, insulin), and hormone levels (testosterone, DHEA, cortisol) — with results delivered within days and integrated with an app for trend tracking and health guidance. Founded in 2020 by Diedrik Vermeulen and Michael Dubrovsky, SiPhox Health is backed by Khosla Ventures, Intel Capital, and Y Combinator.\n\nSiPhox's current product uses at-home finger-prick blood collection with mail-in testing — customers order a $95 kit, collect a small blood sample at home, and mail it to SiPhox's CLIA-certified lab for analysis. The $16/month membership provides regular testing on a quarterly or customizable schedule, enabling biomarker trend monitoring over time rather than single point-in-time snapshots. The underlying technology vision is a photonic chip (silicon photonics-based biosensor) that would enable instant at-home blood analysis without lab processing, with FDA clearance targeted for 2026.\n\nIn 2025, SiPhox Health competes in the home diagnostics and consumer health testing market with Everlywell (the leading at-home test kit brand), Function Health (comprehensive blood panel membership), InsideTracker, and traditional lab companies (LabCorp, Quest Diagnostics) for consumer blood testing. The longevity and proactive health monitoring movement has driven demand for comprehensive biomarker testing beyond what annual physicals provide. The potential photonic chip breakthrough would represent a significant technological leap — enabling truly point-of-care diagnostics without lab infrastructure. The 2025 strategy focuses on growing the biomarker panel subscription business, advancing the photonic chip development toward FDA clearance, and building clinical evidence for the personalized health intervention recommendations.
Nanterre global concessions and construction (EPA: DG, CAC 40) at €71.6B 2024 revenue record and €4.9B net income; 72 airports/4,400km toll roads with Edinburgh Airport acquisition competing with ACS for global infrastructure concessions.
About
VINCI SA is a Nanterre, France-headquartered global concessions and construction group — listed on Euronext Paris (EPA: DG) as a CAC 40 component — reporting record €71.6 billion in revenue and €4.9 billion in net income for 2024, employing 285,000 people across 120+ countries in three business divisions: Vinci Concessions (€11.7 billion revenue, operating 4,400 km of toll roads and 72 airports including Gatwick and Edinburgh airports in 14 countries), Vinci Energies (€27.5 billion revenue, energy transition and digital infrastructure services), and Vinci Construction (€31.8 billion revenue, civil engineering, buildings, and hydraulic engineering). International markets represent 58% of total revenue. CEO Xavier Huillard has led VINCI since 2010; Pierre Anjolras serves as incoming COO. Key acquisitions include ANA Aeroportos de Portugal (€3.08B, 2012), Gatwick Airport 50.01% (2019), ACS Industrial Services division (€5.2B, 2021), and Edinburgh Airport 50.01% (2024). Founded 1899 as Société Générale d'Entreprises.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.